Literature DB >> 21380540

Aberrant cAMP metabolism in NF1 malignant peripheral nerve sheath tumor cells.

Ian Dang1, George H De Vries.   

Abstract

Malignant peripheral nerve sheath (MPNST) cell lines derived from patients with neurofibromatosis type 1 (NF!) were found to have basal cAMP levels which are two-fold higher than cAMP levels in normal human adult Schwann cells (nHSC). PCR analysis also revealed that normal adult human Schwann cells express mRNA for types Ill, IV, and IX adenylyl cyclase (AC) while NF1 MPNST cells express AC mRNA of types II, V, and VIII in addition to expressing all the isoforms of normal adult human Schwann cells. Further PCR analysis revealed that NF1 MPNST lines express mRNA for EP2 and EP4 prostaglandin receptors whereas nHSC only express mRNA for the EP2 receptor. Exogenous prostaglandins alone or in combination with PDGF BB induced greater increases in cAMP levels and proliferation of NF1 MPNST cells compared to nHSC. We conclude that aberrant cAMP signaling in NF1 MPNST cells contributes to tumor formation in NF1 patients.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21380540     DOI: 10.1007/s11064-011-0433-2

Source DB:  PubMed          Journal:  Neurochem Res        ISSN: 0364-3190            Impact factor:   3.996


  37 in total

1.  Schwann cell proliferative responses to cAMP and Nf1 are mediated by cyclin D1.

Authors:  H A Kim; N Ratner; T M Roberts; C D Stiles
Journal:  J Neurosci       Date:  2001-02-15       Impact factor: 6.167

2.  Aberrant regulation of ras proteins in malignant tumour cells from type 1 neurofibromatosis patients.

Authors:  T N Basu; D H Gutmann; J A Fletcher; T W Glover; F S Collins; J Downward
Journal:  Nature       Date:  1992-04-23       Impact factor: 49.962

3.  A case of neurofibrosarcoma associated with neurofibromatosis: light microscopic, ultrastructural, immunohistochemical and biochemical investigations.

Authors:  N Morioka; T Tsuchida; T Etoh; Y Ishibashi; F Otsuka
Journal:  J Dermatol       Date:  1990-05       Impact factor: 4.005

4.  Reconstitution of the NF1 GAP-related domain in NF1-deficient human Schwann cells.

Authors:  Stacey L Thomas; Gail D Deadwyler; Jun Tang; Evan B Stubbs; David Muir; Kelly K Hiatt; D Wade Clapp; George H De Vries
Journal:  Biochem Biophys Res Commun       Date:  2006-08-02       Impact factor: 3.575

5.  Rescue of a Drosophila NF1 mutant phenotype by protein kinase A.

Authors:  I The; G E Hannigan; G S Cowley; S Reginald; Y Zhong; J F Gusella; I K Hariharan; A Bernards
Journal:  Science       Date:  1997-05-02       Impact factor: 47.728

6.  Murine mast cells secrete a unique profile of cytokines and prostaglandins in response to distinct TLR2 ligands.

Authors:  Salima Mrabet-Dahbi; Martin Metz; Anne Dudeck; Torsten Zuberbier; Marcus Maurer
Journal:  Exp Dermatol       Date:  2009-05       Impact factor: 3.960

7.  Nerve growth factor modifies the expression of inflammatory cytokines by mast cells via a prostanoid-dependent mechanism.

Authors:  J S Marshall; K Gomi; M G Blennerhassett; J Bienenstock
Journal:  J Immunol       Date:  1999-04-01       Impact factor: 5.422

8.  Notch and Schwann cell transformation.

Authors:  Yiwen Li; Prakash K Rao; Rong Wen; Ying Song; David Muir; Peggy Wallace; Samantha J van Horne; Gihan I Tennekoon; Tom Kadesch
Journal:  Oncogene       Date:  2004-02-05       Impact factor: 9.867

9.  Neurofibrosarcoma-derived Schwann cells overexpress platelet-derived growth factor (PDGF) receptors and are induced to proliferate by PDGF BB.

Authors:  A Badache; G H De Vries
Journal:  J Cell Physiol       Date:  1998-11       Impact factor: 6.384

10.  PKA phosphorylation and 14-3-3 interaction regulate the function of neurofibromatosis type I tumor suppressor, neurofibromin.

Authors:  Liping Feng; Shunji Yunoue; Hiroshi Tokuo; Tatsuya Ozawa; Dongwei Zhang; Siriporn Patrakitkomjorn; Toru Ichimura; Hideyuki Saya; Norie Araki
Journal:  FEBS Lett       Date:  2004-01-16       Impact factor: 4.124

View more
  11 in total

Review 1.  Molecular mechanisms promoting the pathogenesis of Schwann cell neoplasms.

Authors:  Steven L Carroll
Journal:  Acta Neuropathol       Date:  2011-12-11       Impact factor: 17.088

2.  In vitro modeling of hyperpigmentation associated to neurofibromatosis type 1 using melanocytes derived from human embryonic stem cells.

Authors:  Jennifer Allouche; Nathalia Bellon; Manoubia Saidani; Laure Stanchina-Chatrousse; Yolande Masson; Anand Patwardhan; Floriane Gilles-Marsens; Cédric Delevoye; Sophie Domingues; Xavier Nissan; Cécile Martinat; Gilles Lemaitre; Marc Peschanski; Christine Baldeschi
Journal:  Proc Natl Acad Sci U S A       Date:  2015-07-06       Impact factor: 11.205

Review 3.  Sensitization of Ion Channels Contributes to Central and Peripheral Dysfunction in Neurofibromatosis Type 1.

Authors:  Aubin Moutal; Erik T Dustrude; Rajesh Khanna
Journal:  Mol Neurobiol       Date:  2016-05-11       Impact factor: 5.590

Review 4.  Genetically engineered mouse models shed new light on the pathogenesis of neurofibromatosis type I-related neoplasms of the peripheral nervous system.

Authors:  Nicole M Brossier; Steven L Carroll
Journal:  Brain Res Bull       Date:  2011-08-10       Impact factor: 4.077

5.  Integrated proteomics identified novel activation of dynein IC2-GR-COX-1 signaling in neurofibromatosis type I (NF1) disease model cells.

Authors:  Mio Hirayama; Daiki Kobayashi; Souhei Mizuguchi; Takashi Morikawa; Megumi Nagayama; Uichi Midorikawa; Masayo M Wilson; Akiko N Nambu; Akiyasu C Yoshizawa; Shin Kawano; Norie Araki
Journal:  Mol Cell Proteomics       Date:  2013-01-28       Impact factor: 5.911

Review 6.  Neurofibromin and suppression of tumorigenesis: beyond the GAP.

Authors:  Juan Mo; Stefanie L Moye; Renee M McKay; Lu Q Le
Journal:  Oncogene       Date:  2022-01-23       Impact factor: 8.756

7.  Double NF1 inactivation affects adrenocortical function in NF1Prx1 mice and a human patient.

Authors:  Karolina Kobus; Daniela Hartl; Claus Eric Ott; Monika Osswald; Angela Huebner; Maja von der Hagen; Denise Emmerich; Jirko Kühnisch; Hans Morreau; Frederik J Hes; Victor F Mautner; Anja Harder; Sigrid Tinschert; Stefan Mundlos; Mateusz Kolanczyk
Journal:  PLoS One       Date:  2015-03-16       Impact factor: 3.240

8.  Nf1 RasGAP inhibition of LIMK2 mediates a new cross-talk between Ras and Rho pathways.

Authors:  Béatrice Vallée; Michel Doudeau; Fabienne Godin; Aurélie Gombault; Aurélie Tchalikian; Marie-Ludivine de Tauzia; Hélène Bénédetti
Journal:  PLoS One       Date:  2012-10-17       Impact factor: 3.240

Review 9.  Recent Advances in the Diagnosis and Pathogenesis of Neurofibromatosis Type 1 (NF1)-associated Peripheral Nervous System Neoplasms.

Authors:  Jody F Longo; Shannon M Weber; Brittany P Turner-Ivey; Steven L Carroll
Journal:  Adv Anat Pathol       Date:  2018-09       Impact factor: 4.571

10.  Multiscale, converging defects of macro-porosity, microstructure and matrix mineralization impact long bone fragility in NF1.

Authors:  Jirko Kühnisch; Jong Seto; Claudia Lange; Susanne Schrof; Sabine Stumpp; Karolina Kobus; Julia Grohmann; Nadine Kossler; Peter Varga; Monika Osswald; Denise Emmerich; Sigrid Tinschert; Falk Thielemann; Georg Duda; Wenke Seifert; Thaqif El Khassawna; David A Stevenson; Florent Elefteriou; Uwe Kornak; Kay Raum; Peter Fratzl; Stefan Mundlos; Mateusz Kolanczyk
Journal:  PLoS One       Date:  2014-01-21       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.